|View printer-friendly version|
|BioLineRx to Present at 2016 Annual Roth Conference in Southern California on March 14|
A live webcast of the presentation will be available on BioLineRx's website. A replay will be available one hour after the presentation ends and will be accessible for three months following the presentation.
Investors attending the conference that wish to meet with Dr. Savitsky and Mr. Serlin for a one-on-one meeting should contact the Roth conference team at email@example.com.
BioLineRx is a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in
BioLineRx's leading therapeutic candidates are: BL-8040, a cancer therapy platform, which is in the midst of a Phase 2 study for relapsed/refractory AML, has recently initiated a Phase 2b study as an AML consolidation treatment, has recently initiated a Phase 1/2 study in hMDS and AA, and has successfully completed a Phase 1 study in stem cell mobilization; and BL-7010 for celiac disease, which has successfully completed a Phase 1/2 study. In addition, BioLineRx has a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates, and has recently announced an immuno-oncology collaboration with Merck for the combination of BL-8040 and Keytruda in pancreatic cancer.
For more information on BioLineRx, please visit http://www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company's